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Abstract
Introduction: Rheumatoid arthritis (RA) is associated with changes in body composition and bone mineral density
(BMD). The purpose of the present study was to evaluate whether anti-TNF treatment in early RA has an impact on
body composition and BMD besides that which could be achieved by intensive disease-modifying anti-rheumatic
drug (DMARD) combination therapy.
Methods: Forty patients with early RA who failed treatment with methotrexate up to 20 mg/week for 3 months
were randomised to addition of sulphasalazine and hydroxychloroquine (treatment A) or addition of infliximab
(treatment B). At 3, 12 and 24 months, body composition and BMD were assessed by total-body dual-energy X-ray
absorptiometry. At the same time points, leptin, adiponectin, apolipoproteins, insulin-like growth factor-1 (IGF-1)
and markers of bone remodelling were analysed. Compliance to treatment was considered in the analyses. Data
were analysed with a mixed, linear model.
Results: Patients treated with anti-TNF had a significant increase in fat mass at 2 years, 3.8 (1.6 to 5.9) kg, in
contrast to patients in treatment A, 0.4 (-1.5 to 2.2) kg (P = 0.040), despite similar reduction in disease activity. Both
treatment strategies prevented loss of muscle mass and bone. Leptin concentrations increased significantly in both
groups at 2 years and adiponectin increased significantly at 2 years in treatment A and at 1 year in treatment B.
There were no significant changes in apolipoproteins or IGF-1. The markers of bone resorption decreased at 12
months in both treatment groups with no significant difference between the treatment groups.
Conclusions: Infliximab therapy increased body fat mass, an effect that was not achieved with the combination of
DMARDs, despite a similar reduction in disease activity, and thus seemed to be drug specific. The increase of fat
mass was not associated with an exacerbated atherogenic lipid profile. Leptin and adiponectin concentrations
increased in both treatment groups. The increase of adiponectin may partially explain the reduced frequency of
cardiovascular diseases found when disease activity is reduced in RA.
Trial registration: ISRCTN39045408.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease associated with changes in body composition [1]
and decreased bone mineral density (BMD) [2].
The change in body composition with loss of skeletal
muscle mass and accumulation of fat is known as rheu-
matoid cachexia and is associated with increased disabil-
ity, morbidity and mortality [1,3]. Increased fat mass,
especially abdominal fat mass, thus increases the risk for
type 2 diabetes and cardiovascular diseases (CVD) [4].
CVD has turned out to be one of the most important
causes of death in RA patients [5]. Furthermore, loss of
body protein is associated with muscle weakness and
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morbidity and mortality [1]. The combination of fat
mass gain and reduced muscle mass may compound
these individual risks [6].
The changes in body composition and BMD have
been regarded to be consequences of the catabolic pro-
cess induced by the chronic inflammatory disease and
especially attributed to proinflammatory cytokines, like
TNFa, and physical inactivity [1]. If so, treatments that
reduce inflammation should normalise the deranged
body composition and hamper bone loss. In this context
it is especially interesting to investigate whether treat-
ment with TNF antagonists, which powerfully reduces
disease activity in RA [7], might have this potency.
Recently, treatment with anti-TNF in patients with
early as well as longstanding RA has been reported not
to affect body composition [8-10]. The treatment peri-
ods were only 3 to 12 months, however, which probably
is too short a time to detect significant changes. This
suggestion is strengthened by the fact that anti-TNF
treatment during 2 years in patients with spondyloar-
thropathy resulted in significant increase in body weight
mainly due to gain in fat mass [11]. A possibility is that
the new therapeutic strategies contribute to body fat
gain by controlling weight loss in patients that still have
decreased physical activity [12]. The study on spondy-
loarthropathy was uncontrolled and could not differenti-
ate between a specific effect of TNF antagonists and a
general effect of reduced inflammatory activity [11].
The primary objective of the present study was to
investigate whether infliximab had any effects on body
composition and BMD beyond the anti-inflammatory
effect in patients with early RA. The patients were ran-
domised to intensive treatment with methotrexate
(MTX) in combination with sulphasalazine and hydroxy-
chloroquine or to MTX in combination with infliximab.
The patients were analysed regarding changes in body
composition and BMD after 9 and 21 months, consider-
ing whether they were compliant to their respective
treatment or not. Secondary objectives were to analyse
whether infliximab affected levels of adipokines and apo-
lipoproteins, substances of importance for CVD, as well
as levels of biomarkers of bone metabolism and insulin-
like growth factor-1 (IGF-1), and whether such changes
were related to changes in body composition and BMD.
Materials and methods
Patients
Forty out of 44 consecutive patients with early RA who
participated in the Swefot (Swedish Pharmacotherapy)
s t u d ya tK a r o l i n s k aU n i v e r s i t yH o s p i t a lw e r ei n c l u d e d
between April 2004 and October 2005.
Swefot is an open, multicentre, randomised study
designed to compare two treatment strategies in patients
in whom MTX up to 20 mg/week had not lowered the
Disease Activity Score of 28 joints (DAS28) to ≤3.2 dur-
ing the first 3 months of disease treatment [13]. After
3 months, the patients who had not achieved low dis-
ease activity were randomised by block randomisation
for each centre according to a central randomisation
programme: treatment A, MTX with addition of sulpha-
salazine 2,000 mg/day and hydroxychloroquine 400 mg
daily; and treatment B, MTX with the addition of the
TNF antagonist infliximab 3 mg/kg body weight given
intravenously at weeks 0, 2 and 6 and every 8 weeks
thereafter. The patients had RA according to the Ameri-
can College of Rheumatology criteria [14], had disease
duration <12 months and had active disease defined as
DAS28 >3.2.
Forty patients were eligible to inclusion in this sub-
s t u d ya st h e yw e r ea s s e s s e db yd u a lX - r a ya b s o r p t i o m e -
try measurements and had started treatment according
to the randomisation (Figure 1). Of these patients, 22
had been randomised to treatment A and 18 to treat-
ment B. At 24 months, two of the patients with treat-
ment B had changed from infliximab to etanercept. The
reasons for withdrawal from the protocol treatment are
shown in Figure 1. Three of the evaluated patients (one
patient with treatment A and two patients with treat-
ment B) received treatment with glucocorticoids (5 to
7.5 mg daily), and two patients were treated with
bisphosphonates, both with treatment B. Three patients
were treated with lipid-lowering drugs, one with treat-
ment A and two with treatment B.
The study was approved by the Karolinska University
Hospital ethics committee and was performed in accor-
dance with the Helsinki Declaration. All patients received
verbal and written information on the trial and signed a
consent form prior to inclusion. The trial is registered in
the ISRCTN register (number ISRCTN39045408).
Clinical assessments
Disease activity was assessed by the DAS28 [15], and
functional status was measured using the Swedish ver-
sion of the Stanford Health Assessment Questionnaire
(HAQ) [16].
Body composition assessments
The body mass index (BMI) was calculated and defined
as low (<18.5 kg/m
2), normal (18.5 to 24.9 kg/m
2)o r
high (>25 kg/m
2) [17]. Body composition was measured
by dual X-ray absorptiometry with a densitometer (GE-
Lunar Progedy, Maddison, MA, USA). Fat mass (FM),
lean body mass (LBM), bone mineral content and BMD
were assessed at the 3-month, 1-year and 2-year visits.
The appendicular lean mass was calculated by adding
lean mass from both arms and legs. Fat-free mass
(FFM), the sum of LBM and bone mineral content, was
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(FMI) as well as the fat-free mass index (FFMI) were
calculated [18]. Fat from arms and legs were summed to
estimate peripheral fat, and a trunk/peripheral fat ratio
was created by dividing trunk regional fat by peripheral
regional fat.
BMD values were given in grams of bone mineral per
square centimetre, as T scores (the number of standard
Figure 1 Distribution of the study patients by treatment group. DXA, Dual X-ray absorptiometry.
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Page 3 of 11deviations (SDs) from the mean in healthy young sex-
matched people) and as Z scores (the number of SDs
from the mean of healthy age-matched and sex-matched
people); values obtained from the Lunars combined Eur-
opean/US reference population [19].
Body composition definitions
The reference value for FM percentage is 20 to 30% for
women and 12 to 20% for men [20]. Overweight is
defined as FM > 33% for women and FM > 25% for
men. Obesity for persons younger than 60 years is
defined as FM > 41% for women and FM > 29% for
men, and for persons older than 60 years as FM > 43%
for women and FM > 31% for men [21].
Trunk/peripheral fat ratios for healthy Swedish
women and men are mean (95% confidence interval) of
0.91 (0.87, 0.95) and 1.34 (1.25, 1.44), respectively [22].
A higher trunk/peripheral fat ratio indicates central obe-
sity. Data from a Swiss population of healthy adults
(2,986 men, 2,649 women) were used to classify the
patients as underlean or having excess FM [18]. The
cut-off point for low muscle mass was defined as a
FFMI below the 10th percentile and obesity was defined
as a FMI above the 90th percentile. Underlean implies
muscle wasted (that is, insufficient muscle mass).
Osteoporosis was defined as a T score ≤-2.5 SDs [23]
and osteopenia as a T score <-1.0 SD from the mean in
healthy, young, sex-matched people.
Assays on blood samples
Serum samples were obtained between 9:00 am and 3:00
pm and were stored at -70°C until all samples were ana-
lysed. Leptin, adiponectin and IGF-1 were analysed at
the Rolf Luft Center for Diabetes Research, Department
of Molecular Medicine and Surgery, Karolinska Institu-
tet, and apolipoproteins and bone markers were ana-
lysed at the Study Centre for Laboratory Medicine,
Karolinska University Hospital, both in Stockholm,
Sweden.
Leptin was determined by radioimmunoassay using
HL-81K (Linco Research, Inc, St Charles, Missouri,
USA). Normal mean (SD) leptin values (BMI ranges 18
to 25) are for lean men 3.8 (1.8) μg/l and for lean
women 7.4 (3.7) μg/l. Levels rise approx 2.5 times faster
in women per unit BMI as compared with men [24].
Adiponectin was determined by radioimmunoassay
using HADP-61 (Linco Researc h ,I n c ,S tC h a r l e s ,M i s -
souri, USA). The sensitivity of the assay is 1 ng/ml.
Mean (SD) levels from 205 Swedish healthy adults (106
women, 99 men) are for women 11.88 (4.69) mg/l and
for men 7.34 (3.55) mg/l (AL Unden and K Brismar,
personal communication). The intra-assay precision
coefficient of variation (CV) is 3.86% and the inter-assay
precision CV 8.47%.
Apolipoprotein A1 (apoA1) and apolipoprotein B (apoB)
were determined by Synchrone LX from Beckman AB
(Fullerton, California, USA) using turbidimetry. The refer-
ence intervals for apoA1 and apoB were given by the man-
ufacturer. The apoA1 reference intervals are for women
1.10 to 2.10 g/l and for men 1.10 to 1.80 g/l. The apoB
reference interval was determined by Synchrone LX from
Beckman AB using turbidimetry. The reference interval
for individuals younger than 40 years is 0.50 to 1.50 g/l
and for individuals 40 years and older is 0.50 to 1.70 g/l.
The apoB/apoA1 ratio was calculated. A ratio >0.6 for
women and >0.7 for men is considered a moderate risk
for CVD, and the risk increases almost linearly with
increasing ratio. For patients with other risk factors for
CVD, the preferable ratio should be even lower [25].
The bone markers analysed were procollagen type I N-
terminal propeptide (P1NP) as a marker of bone forma-
tion, and C-terminal telopeptide crosslaps (CTX-1) as
well as C-terminal telopeptides of type I collagen (1CTP)
as markers of bone degradation. Reference intervals for
the bone markers were given by the manufacturer.
P1NP was determined by the Elecsys 1010/2010 total
P1NP serum kit from Roche Diagnostics (Mannheim,
Germany), which employs the electrochemiluminescence
immunoassay technique. The measuring range is 5 to
1,200 μg/l. The reference intervals are for premenopau-
sal women <60 μg/l, for postmenopausal women <80
μg/l and for men <45 μg/l. The intra-assay CV is 2.3%
and the total precision CV is 2.9%.
CTX-1 was determined by the Elecsys 1010/2010 b-
CrossLaps serum kit from Roche Diagnostics, which
also employs the electrochemiluminescence immunoas-
say technique. The measuring range is 10 to 6,000 pg/
ml. The sensitivity of the assay is 0.01 ng/ml. The refer-
ence intervals are for premenopausal women <570 pg/
ml and for postmenopausal women <1,000 pg/ml, and
for men younger than 50 years of age <580 pg/ml, for
men between 50 and 70 years old <700 pg/ml and for
men older than 70 years <850 pg/ml. The intra-indivi-
dual CV is 17.9%. The intra-assay CV is 2.4% and the
total precision CV 3.1%.
1CTP was determined by the Multigamma radioim-
munoassay kit from Orion Diagnostica (Espoo, Finland).
The sensitivity of the assay is 0.5 μg/l. The reference
interval is 1.8 to 5.0 μg/l. The intra-assay CV and the
inter-assay CV are 5.3% and 4.25%, respectively.
The anabolic factor IGF-1 was determined by radioim-
munoassay, after separation of insulin-like growth factor
from its binding proteins by acid ethanol extraction and
cryoprecipitation. To minimise interference of remaining
insulin-like growth factor binding proteins, des(1-3)-IGF-1
was used as the radioligand [26]. The intra-assay and
inter-assay CVs were 4% and 11%. As serum levels of IGF-
1 are age dependent, decreasing with age, IGF-1 values
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from the regression of the values of 247 healthy adult sub-
jects [27].
Statistical analysis
All eligible patients, regardless of compliance with the
protocol, were included in the analyses. STATISTICA
release 8 (Stat Soft Scandinavia AB, Tulsa, OK, USA) and
SAS System 9.1 (SAS Institute Inc., Cary, NC, USA) were
used for statistical analyses. Data are presented as mean
(SD) or median (interquartile range) depending on their
distribution. Correlation analysis was performed with
Spearman rank order correlations. Area under the curve
(AUC) analyses were calculated according to the trape-
zoidal rule and included values from time points 0, 3, 12
and 24 months. Data were analysed using a mixed linear
model [28] with two between-group factors - Treatment
(A and B) and Compliance (<24 months and 24 months)
- and one within-group factor - Time (3 months, 12
months and 24 months). Different covariance models
were tested and the covariance structure with the smal-
lest value of the Akaike’s Information Criterion (AICC
and BIC) was considered to best fit the data. In case of
significant interactions, simple main effect tests were per-
formed; that is, the effects of one factor holding the level
of the other factors fixed. Results are presented as mean
(standard error) and 95% confidence interval. The distri-
bution of some variables was positively skewed and
before the formal analyses the variables were log-trans-
formed. P < 0.05 was considered statistically significant.
Results
At baseline and the 3-month visit, the time for randomi-
sation, the two treatment groups were well balanced as
regards demographic and clinical variables (Table 1).
Body mass index and body composition
BMI and body composition data at the 3-month visit are
presented in Table 2. At the 3-month visit, 50% of the
patients had a BMI corresponding to overweight (BMI >
25 kg/m
2). Of the women, 76% had a FM percentage
corresponding to overweight and 24% corresponding to
obesity. The figures for men were 91% and 64%, respec-
tively. Twenty percent of the patients (seven women,
one man) had low muscle mass, FFMI below the 10th
percentile of the reference population.
Changes in body composition and BMD are presented
in Table 3. The patients compliant to treatment A had
at 12 months a significant increase in FFM compared
with the 3-month visit, an increase that was still present
at 24 months.
The patients compliant to treatment B had a signifi-
cant increase in FM and FMI at both 12 and 24 months,
compared with the 3-month visit.
When comparing the treatment groups, there were
no statistical significant differences in changes of BMI
or body composition from 3 to 12 months. The
changes from 3 to 24 months, however, were signifi-
cantly different between the treatment groups as
regards the increase in FM and FMI (P = 0.040 and P
= 0.035, respectively), where FM increased mean (SD)
3.4 (1.4) kg more in the patients in group B compared
with patients in group A. Changes in LBM and FFM
did not differ significantly between the treatment
groups.
Bone mineral density
At the 3-month visit, 10% of the patients had osteoporo-
sis and 48% osteopenia.
The patients compliant to treatment A had at 24
months a significant increase in Z score at lumbar
Table 1 Demographic, clinical and laboratory
characteristics for patients at baseline and at the 3-
month visit (time for randomisation)
Treatment A
(n = 22)
Treatment B
(n = 18)
Baseline
Age (years) 59.5 (58.0 to 67.0) 56.0 (42.0 to 73.0)
Women 16 (73%) 13 (72%)
Menopause 14 (88%) 8 (62%)
Current or previous smoker 15(68%) 7 (41%)
Disease duration (months) 5.4 (2.9) 4.9 (3.4)
Rheumatoid factor positivity 11 (50%) 10 (56%)
X-ray criteria at baseline 7 (32%) 2 (11%)
3-month visit
Erythrocyte sedimentation
rate (mm)
25.0 (14.0 to 29.0) 23.5 (12.0 to 34.0)
Disease Activity Score of 28
joints
4.3 (4.1 to 4.9) 4.8 (3.7 to 5.1)
HAQ score 0.86 (0.50) 0.89 (0.18)
Leptin (μg/l) 8.8 (5.4 to 27.7) 7.9 (3.9 to 14.2)
Adiponectin (mg/l) 10.7 (3.4) 10.9 (6.6)
Apolipoprotein A1 (g/l) 1.46 (0.25) 1.64 (0.23)
Apolipoprotein B (g/l) 1.10 (0.26) 1.03 (0.21)
Apolipoprotein B/
apolipoprotein A1
0.77 (0.24) 0.64 (0.15)
P1NP (μg/l) 46 (36 to 58) 43 (32 to 68)
CTX-1 (pg/ml) 280 (191 to 368) 233 (119 to 457)
1CTP (μg/l) 4.1 (3.3 to 5.6) 3.7 (2.9 to 4.9)
IGF-1 (μg/l) 145.5 (114.0 to
166.0)
154.5 (130.0 to
193.0)
IGF-1 SD scores -0.09 (1.34) -0.07 (-0.12)
Demographic, clinical and laboratory characteristics at baseline and at the 3-
month visit (time for randomisation). Data presented as median (interquartile
range), n (%) or mean (standard deviation (SD)). Treatment A, methotrexate +
sulphasalazine + hydroxychloroquine; treatment B, methotrexate + infliximab.
HAQ, Health Assessment Questionnaire, P1NP, procollagen type I N-terminal
propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal
propeptide of type I collagen; IGF-1, insulin-like growth factor-1.
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Page 5 of 11spine, compared with the 3-month visit (Table 3). The
patients compliant to treatment B had a trend for an
increase in BMD and Z score at the lumbar spine after
24 months. There were no significant changes at the
femoral neck between 3 and 24 months in either treat-
ment group. There were no significant differences
between the treatment groups in changes in bone
mineral at either skeletal site between the randomisation
and the 24-month follow-up (Table 3).
Inflammatory activity and disability
Table 4 presents the results after 24 months of rando-
mised treatment. The DAS28 and the HAQ score
decreased during the study period in both treatment
groups and there were no significant differences in
changes in inflammatory activity or disability between
the treatment groups.
After 12 months of treatment, 38% of patients compliant
to treatment A and 25% of patients compliant to treat-
ment B had received remission (DAS28 < 2.6). The fre-
quencies after 24 months were 50% and 73%, respectively.
There was no significant difference between the treatment
groups in remission frequency at either time point.
Leptin
At randomisation, the leptin levels for lean women were
median (interquartile range) 5.9 (3.1 to 13.3) μg/l
whereas for lean men the levels were 3.1 (2.7 to 4.7) μg/l.
When including all patients, irrespective of BMI, the
levels were median (interquartile range) 13.9 (5.5 to 23.9)
μg/l for women and 5.4 (3.1 to 6.8) μg/l for men.
Leptin increased significantly from 3 to 24 months in
treatment group A, whereas in treatment group B there
was a significant increase from 3 to 12 months as well
as from 3 to 24 months. There was no significant differ-
ence in changes in leptin levels between the treatment
groups (Table 4).
Adiponectin
At randomisation, the adiponectin level for women was
mean (SD) 11.49 (5.29) mg/l. For men, the level was
8.84 (3.65) mg/l.
Adiponectin increased significantly from 3 to 12
months as well as from 3 to 24 months in patients com-
pliant to treatment A, whereas in patients compliant to
treatment B there was a significant increase only
between 3 and 12 months There was no significant dif-
ference in changes in adiponectin levels between the
treatment groups (Table 4).
Apolipoproteins
At randomisation, the apolipoproteins were in the refer-
ence intervals: apoA1 mean (SD) 1.58 (0.26) for women
and 1.42 (0.23) for men, and apoB 0.90 (0.20) for
patients younger than 40 years of age and 1.08 (0.23) for
those older than 40 years.
There was a trend for an increase in apoA1 between 3
and 24 months in patients compliant to treatment B
(Table 4). Change in apoA1 was positively correlated
with the increase in adiponectin from 3 to 24 months (r
= 0.38, P = 0.017). There was no significant change in
apoB during the study period.
At 3 months the apoB/apoA1 ratio was mean (SD)
0.68 (0.22) for women and 0.80 (0.19) for men. There
was a trend for a decrease in the apoB/apoA1 ratio in
patients compliant to treatment A, while the ratio
remained unchanged in patients compliant to treatment
B (Table 4). There were no significant differences in
changes of the apolipoproteins or in apoB/apoA1 ratio
between the treatment groups.
Markers of bone turnover
After 12 months there was a significant decrease in
1CTP in patients compliant to treatment A (P = 0.034)
a n dat r e n df o rad e c r e a s ei nC T X - 1( P =0 . 0 6 0 ) .F o r
patients compliant to treatment B there was a significant
decrease in CTX-1 (P = 0.017) and a trend for a
decrease in 1CTP (P = 0.060). There was no significant
change in P1NP between 3 and 12 months but there
was a trend for a decrease between 3 and 24 months in
treatment group B (P = 0.08). The P1NP/CTX-1 ratio
Table 2 Body composition and bone mineral density at
the 3-month visit (time for randomisation)
Treatment A
(n = 22)
Treatment B
(n = 18)
Body mass index (kg/m
2) 27.7 (6.4) 24.7 (3.7)
Fat mass (kg) 30.5 (12.9) 24.4 (7.5)
Fat mass index (kg/m
2) 10.9 (4.8) 8.7 (2.9)
Fat (%) 38.8 (8.3) 35.7 (7.9)
Trunk:peripheral fat ratio 1.3 (0.3) 1.2 (0.4)
Trunk fat (kg) 16.4 (7.2) 13.9 (6.6)
Lean body mass (kg) 45.8 (8.8) 43.4 (9.0)
Appendicular lean mass (kg) 19.9 (4.4) 18.7 (4.4)
Fat-free mass (kg) 48.3 (9.1) 45.9 (9.4)
Fat-free mass index (kg/m
2) 17.0 (2.5) 16.1 (2.1)
L2 to L4
Bone mineral density (g/
cm
2)
1.18 (0.19) 1.06 (0.14)
Z score 0.68 (1.40) -0.66 (0.89)
T score -0.31 (1.55) -1.26 (1.18)
Femoral neck
Bone mineral density (g/
cm
2)
0.98 (0.16) 0.92 (0.11)
Z score 0.50 (1.04) -0.16 (0.79)
T score -0.32 (1.25) -0.82 (0.95)
Data presented as mean (standard deviation). Treatment A, methotrexate +
sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab.
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treatment group B (P = 0.032) and there was a trend for
an increase also in treatment group A (P = 0.09).
The changes in markers of bone resorption and for-
mation between 3 and 24 months are shown in Table 4.
There were no significant changes in markers of bone
resorption between 3 and 24 months, and no significant
difference in changes in markers of bone turnover or
ratios of bone markers between the treatment groups
during the study period (Table 4).
Table 4 Changes in different variables between 3 and 24 months, using a mixed linear model
P value
Treatment A (n = 14) Treatment B (n = 11) Time Treatment × Compliance × Time
DAS28 -1.8 (-2.6 to -1.0) -1.9 (-2.8 to -1.0) <0.001 0.59
ESR
a -0.62 (-1.07 to -0.18) -0.49 (-0.99 to 0.02) 0.003 0.78
HAQ -0.27 (-0.50 to -0.04) -0.43 (-0.69 to -0.17) <0.001 0.82
Leptin
a 0.25 (0.02 to 0.48) 0.32 (0.05 to 0.59) <0.001 0.07
Adiponectin 1.66 (0.16 to 3.17) 2.33 (-0.27 to 4.93) <0.001 0.058
Apolipoprotein A1 0.09 (-0.08 to 0.26) 0.19 (-0.01 to 0.39) 0.004 0.45
Apolipoprotein B -0.06 (-0.16 to 0.03) 0.07 (-0.04 to 0.18) 0.59 0.33
ApoB/ApoA1 0.09 (-0.19 to 0.00) -0.01 (-0.12 to 0.10) 0.023 0.56
P1NP
a -0.02 (-0.030 to 0.25) -0.29 (-0.61 to 0.03) 0.004 0.82
CTX1
a -0.25 (-0.64 to 0.14) -0.47 (-0.62 to 0.28) <0.001 0.11
1CTP
a -0.05 (-0.27 to 0.16) -0.21 (-0.46 to 0.04) <0.001 0.76
P1NP/CTX-1
a 0.23 (-0.04 to 0.49) -0.10 (-0.41 to 0.21) 0.023 0.08
P1NP/1CTP
a 0.03 (-0.28 to 0.34) -0.08 (-0.44 to 0.28) 0.45 0.56
IGF-1
a 0.06 (-0.07 to 0.18) -0.02 (-0.17 to 0.13) 0.050 0.08
IGF-1 SD score 0.32 (-0.14 to 0.78) 0.02 (-0.52 to 0.56) 0.003 0.12
Data presented as mean (95% confidence interval).
aArithmetic mean. Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B,
methotrexate +infliximab. DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire;a p o ,
apolipoprotein; P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen;
IGF-1, insulin-like growth factor-1; SD, standard deviation. Changes between 3 and 12 months and patients not compliant to respective treatment are not
presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant.
Table 3 Changes in body composition and bone mineral density between 3 and 24 months
P value
Treatment A (n = 14) Treatment B (n = 11) Time Treatment × Compliance × Time
Body mass index (kg/m
2) 0.54 (-0.37 to 1.44) 0.89 (-0.13 to 1.91) 0.07 0.37
Fat mass (kg) 0.36 (-1.54 to 2.25) 3.77 (1.63 to 5.90) 0.028 0.040
Fat mass index (kg/m
2) 0.05 (-0.62 to 0.72) 1.24 (0.48 to 2.00) 0.035 0.035
Fat (%) 0.15 (-2.03 to 1.73) 2.80 (0.67 to 4.91) 0.11 0.17
Trunk/peripheral fat ratio 0.15 (-0.05 to 0.36) 0.18 (-0.05 to 0.42) 0.18 0.82
Trunk fat (kg) -0.01 (-1.26 to 1.25) 1.11 (-1.95 to 4.17) 0.40 0.36
Lean body mass (kg) 1.12 (-0.06 to 2.30) 0.52 (-0.81 to 1.86) 0.007 0.79
Appendicular lean mass (kg) 0.08 (-0.65 to 0.80) 0.25 (-0.56 to 1.07) 0.26 0.83
Fat-free mass 1.23 (0.08 to 2.38) 0.57 (-0.73 to 1.87) 0.004 0.69
Fat-free mass index 0.29 (-0.15 to 0.72) 0.16 (-0.33 to 0.65) 0.011 0.63
L2 to L4
BMD (g/cm
2) 0.02 (-0.01 to 0.05) 0.03(0.00 to 0.06) 0.15 0.56
Z score 0.31 (0.06 to 0.57) 0.29 (0.00 to 0.58) 0.030 0.26
T score 0.26 (-0.03 to 0.55) 0.26 (-0.03 to 0.55) 0.20 0.55
BMD (g/cm
2) 0.00 (-0.02 to 0.02) 0.01 (-0.03 to 0.01) 0.19 0.63
Z score 0.12 (-0.06 to 0.30) 0.04 (-0.24 to 0.17) 0.24 0.63
T score 0.01 (-0.14 to 0.17) 0.12 (-0.29 to 0.06) 0.20 0.32
Changes in body composition and bone mineral density (BMD) between 3 and 24 months, using a mixed linear model. Data presented as mean (95% confidence
interval). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. Changes between 3 and 12 months and
patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor
Time. Bold values are statistically significant.
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The mean IGF-1 at baseline corresponded to a mean
IGF-1 SD score within the normal range of the refer-
ence population. IGF-1 remained unchanged during the
study period and there was no difference in change in
IGF-1 between the treatment groups (Table 4).
Correlations between body composition and BMD and
clinical and laboratory variables at randomisation for all
patients
Leptin correlated positively and significantly with most
variables of fat (FM r = 0.78, P < 0.001). Adiponectin
was significantly negatively correlated with the trunk/
peripheral fat ratio (r = -0.42, P = 0.006). There were no
significant correlations between FM and disease dura-
tion, markers of inflammation, HAQ score, apolipopro-
teins or IGF-1. There was a positive correlation between
age and FMI (r = 0.33, P = 0.040).
There were no significant correlations between LBM,
appendicular lean mass, FFM or FFMI and age, disease
duration, markers of inflammation, HAQ score or IGF-1.
There was a positive correlation between leptin and Z
score at the lumbar spine (r = 0.39, P = 0.015). There
were no other significant correlations between BMD at
the lumbar spine or total hip and disease duration, mar-
kers of inflammation, HAQ score, IGF-1 or markers of
bone turnover.
Correlations between changes in body composition and
BMD and AUC of different variables
The AUC values were calculated from the values at time
points 0, 3, 12 and 24 months.
High AUC values for apoB and the apoB/apoA1 ratio
were associated with increased trunk/peripheral fat ratio
(r = 0.43, P =0 . 0 0 6a n dr =0 . 4 6 ,P = 0.003, respec-
tively). All fat variables, except the trunk/peripheral fat
ratio, were significantly positively correlated with adipo-
nectin - the highest correlation coefficient being with fat
percentage (r = 0.39, P = 0.013). AUC values for the
erythrocyte sedimentation rate, DAS28, HAQ score,
IGF-1, leptin and apolipoproteins did not significantly
correlate with changes in FM, FMI, trunk fat or periph-
eral fat.
AUC values for the erythrocyte sedimentation rate,
DAS28, HAQ score and IGF-1 did not significantly cor-
relate with changes in LBM, appendicular lean mass,
FFM or FFMI.
There were significant correlations between the AUC
for P1NP and changes in BMD at the lumbar spine and
femoral neck (r = -0.34, P =0 . 0 4 0a n dr = -0.35, P =
0.031, respectively), whereas there were no significant
correlations between markers of bone resorption and
BMD. AUC values for the erythrocyte sedimentation
r a t e ,D A S 2 8 ,H A Qs c o r e ,l e p t i na n dI G F - 1d i dn o t
significantly correlate with changes in BMD at lumbar
spine or femoral neck.
Discussion
In this prospective randomised study of early RA fol-
lowed during 2 years, patients treated with infliximab
had a significant increase in FM. That was not the case
in patients treated with MTX in combination with sul-
phasalazine and hydroxychloroquine, despite a similar
reduction of disease activity. Both treatment strategies
prevented loss of skeletal muscle mass and bone.
The analyses showed a specific effect of anti-TNF
treatment on body composition with an increase of FM,
an effect that has not been shown previously in RA with
shorter treatment periods [8-10]. In spondylarthropathy,
however, patients gained fat during 2 years of treatment
with TNF antagonists [11] - but being without a control
group, clarifying the role of anti-TNF versus control of
the inflammatory activity was impossible. The lack of fat
gain in the present patients on the combination treat-
ment A therapy, despite a similar reduction of disease
activity, indicates that the fat gain in the anti-TNF-trea-
ted patients was drug specific.
Adipose tissue secretes a variety of biologically active
proteins, called adipokines, including leptin, adiponectin
and TNFa [29]. Plasma leptin levels are reported to
directly correlate with degree of adiposity in healthy
humans [30]. Such a correlation was also present in the
RA patients at the 3-month visit. The leptin AUC for 0
to 24 months did not correlate with changes in FM dur-
ing 3 to 24 months, however, probably dependent on
the fact that leptin levels increased in both treatment
groups but FM increased only in the anti-TNF-treated
patients. This hypothesis suggests a disruption between
leptin levels and adiposity secondary to inflammation
and/or anti-TNF therapy. In chronic inflammation, such
as RA, leptin levels have been shown to be negatively
correlated with inflammation [31]. This finding could
explain the increasing levels seen when disease activity
decreased and may also explain why leptin increased in
treatment group A despite stable weight.
Anti-TNF therapy over 3 and 6 months has earlier
been reported not to alter leptin concentrations [32,33],
which is in contrast to the increase found here. This dif-
ference could possibly be ascribed to different lengths of
therapy. Three months and 6 months may be too short
a time to obtain a significant increase in FM, which is
the main determinant of circulating levels of leptin.
Adiponectin increased in both treatment groups and
was positively correlated with FM gain during the 21
months of treatment. This increase of adiponectin is
opposite to the decreased levels found in non-RA indivi-
duals with obesity, which is a consequence of downregu-
lation of adiponectin in obesity. Adiponectin has among
Engvall et al. Arthritis Research & Therapy 2010, 12:R197
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tective role in the development of CVD [34,35]. Increase
of adiponectin found here when disease activity
decreased might be one explanation for the reduced fre-
quency of CVD reported in MTX-treated RA patients
[36] as well as during anti-TNF therapy [37]. The evi-
dence that adiponectin has atheroprotective effects in
RA is further supported by the improved endothelial
function in parallel with increasing adiponectin levels
during anti-TNF therapy [38].
The effect of TNF antagonists on adiponectin levels is
contradictory. Both stable levels [32,39,40] and increas-
ing levels [10,38,41] have thus been reported in RA
patients receiving anti-TNF. The explanation for this
discrepancy is unclear, but might depend on different
patient populations as well as varying anti-TNF prepara-
tions. Treatment with MTX has also been shown to
increase the level of adiponectin [42]. Patients with dif-
ferent inflammatory diseases have shown elevated levels
of adiponectin, and it is speculated that the elevated adi-
ponectin is a counteracting mechanism to protect from
harmful effects of different diseases [43].
To investigate whether the gain in FM was associated
with an atherogenic lipid profile, we also analysed
apoA1 and apoB. The apoB/apoA ratio at baseline indi-
cated an increased risk of CVD for both genders. The
ratio remained unchanged in treatment group B,
whereas in treatment group A there was a trend for a
decrease, thus improvement. There was thus no specific
effect of TNF antagonist treatment on this ratio. This
finding is in line with earlier studies, where no or small
changes in lipoproteins in response to anti-TNF seemed
to depend on decreased disease activity [31,44-46]. We
did not study the effects of FM gain on other aspects of
risk factors for CVD, such as insulin sensitivity or
hypertension.
The LBM and FFM were well preserved in both treat-
ment groups. The reason why muscle mass did not
increase when disease activity decreased is probably
dependent on the fact that only 20% of the patients had
l o wm u s c l em a s sf r o mt h es t a r ti nt h i sc o h o r to fe a r l y
RA patients. The stable muscle mass indicates that the
bad influence of factors known to affect muscle mass
negatively - such as inflammation, disability and low
levels of anabolic factors [47] - was under control in
both treatment groups. These effects were probably
achieved by the early intensive treatment of the disease
activity and by reducing disability.
IGF-1 is important to maintain muscle mass and bone
by promoting protein synthesis and inhibiting protein
degradation [48,49]. The local concentration of IGF-1 is
important for its anabolic actions [50], while the
circulating concentration is a useful marker of nutritional
status [51]. The normal serum levels of IGF-1 shown
here indicate adequate energy and protein supplies.
The bone mineral was also well preserved during the
two study years in the two treatment groups. The inten-
sive treatment with powerful reduction of disease activ-
ity thus counteracted bone loss probably as a
consequence of reduced inflammation. Preserved as well
as increased BMD has also been reported after treat-
ment with infliximab for 1 year in patients with estab-
lished RA [52-54].
Biochemical markers of bone turnover provide a com-
plement to measuring BMD, and although their clinical
use has not yet been established they are suggested to
be used in prediction of bone loss and fracture risk
[55,56]. In both treatment strategies, patients had a sig-
nificant decrease in markers of bone turnover. Markers
of bone resorption thus decreased, with unchanged or
increased ratio between P1NP and the resorption mar-
kers. These changes are consistent with those found in
an uncontrolled study evaluating the effect of infliximab
over 12 months in patients with established RA [52].
The reduced bone turnover suggests that both treat-
ments have effects on inflammatory mediated bone loss.
The present study has some limitations. The study
involves a rather small sample of patients but, despite
this, several significant differences between the two
treatment groups were found. On the contrary, because
of the small sample, further differences might be unde-
tectable. Advantages of the present study include that it
is a prospective study over 21 months, which is longer
than previous studies, and that we considered compli-
ance to randomised treatment in the analyses.
Conclusions
Treatment with infliximab increased body FM, an effect
that was not achieved with the combinations of
DMARDs despite similar reduction of disease activity,
and thus seemed to be drug specific. Muscle mass and
BMD were well preserved in both treatment groups.
The increase of FM in the TNF-treated patients was not
associated with an exacerbated atherogenic lipid profile.
F u r t h e rr e s e a r c hi sw a r r a n t e d ,h o w e v e r ,t od e t e r m i n e
whether the increasing FM may be associated with other
risk factors for CVD, such as metabolic syndrome.
There was an increase of leptin and adiponectin con-
centrations in serum in both treatment groups. The
increase of adiponectin suggests improved insulin sensi-
tivity and endothelial function, which may at least par-
tially explain the reduced frequency of CVD found
when disease activity is reduced in RA, and also when
anti-TNF therapy is used.
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